Question 1

Where is the Merck KGaA stock traded?

Accepted Answer

The Merck KGaA stock trades under the ticker MRK.XETRA on the XETRA exchange. ISIN: DE0006599905.

Question 2

What does Merck KGaA do?

Accepted Answer

Merck KGaA is a company characterized by the following investment thesis:

Question 3

What are the key metrics for MRK.XETRA?

Accepted Answer

Key metrics for MRK.XETRA include valuation (P/E 23.5, P/S 2.8, P/B 2), profitability (profit margin 12.08%, ROE 8.53%), and growth (revenue —, earnings —). Market capitalization is 58.37B EUR. These metrics give an overview of the company's financial performance and valuation.

Question 4

How has Merck KGaA's stock price performed?

Accepted Answer

Merck KGaA's stock has returned — over 1 year, — over 3 years, and — over 5 years. Performance can vary depending on market conditions and company developments.

Question 5

How is MRK.XETRA valued?

Accepted Answer

MRK.XETRA has the following valuation metrics: P/E Ratio: 23.5, P/S Ratio: 2.8, P/B Ratio: 2. These metrics help assess whether the stock is fairly valued compared to its fundamentals.

Question 6

Does MRK.XETRA pay dividends?

Accepted Answer

Yes, MRK.XETRA pays dividends with a dividend yield of 1.6%. Dividends can be an important component of the total return on an investment.

Question 7

What are the key risks when investing in MRK.XETRA?

Accepted Answer

Key risks for MRK.XETRA include: Merck KGaA is a diversified German science and technology group spanning Healthcare, Life Sciences, and Electronics. Its competitive landscape fragments by division: large pharma rivals like Roche, Novartis, and Bayer; life-science tools, CDMOs, and lab suppliers including Thermo Fisher, Danaher, and Sartorius; and specialty chemical and electronic-materials suppliers such as BASF. The group carries a layered risk profile—pharmaceutical R&D, patent and regulatory exposure typical of the sector, alongside execution and margin pressures in lab supplies and the cyclical nature of semiconductor and materials markets. Governance considerations and reputational or legal exposures warrant attention, particularly given the Merck family's substantial ownership position.R&D and exclusivity risk: clinical failures or the loss of patent protection in key healthcare programs could materially erode sales and competitive positioning.Life Sciences equipment and consumables face persistent margin pressure from intense competition among dominant players like Thermo Fisher, Danaher, and Sartorius. Large acquisitions—Millipore and Sigma-Aldrich integration being the clearest example—introduce execution risk that can strain operational performance and erode profitability during the integration window. The sector's consolidation creates both scale advantages for incumbents and vulnerability during the messy period when two organizations actually have to function as one.Cyclicality and concentration risk in Electronics/Materials: Semiconductor downturns, supply-chain disruptions, or commodity and energy shocks can sharply depress demand for specialty electronic materials and compress margins.Regulatory, legal and governance risk: The company carries substantial exposure here. Majority family ownership at roughly 70% creates inherent governance asymmetries and minority-shareholder vulnerabilities. Past controversies compound this, and the potential for litigation or regulatory action adds a layer of reputational risk that bears watching.Investors should consider these risk factors carefully before making an investment decision.

Question 8

Who are the main competitors of Merck KGaA?

Accepted Answer

Merck KGaA competes with several listed peers in its sector. Merck KGaA operates across three distinct domains: Life Science (MilliporeSigma), Healthcare, and Electronics (semiconductor and display materials). The company competes against specialized life-science tool providers, contract development and manufacturing organizations, materials vendors, and integrated pharmaceutical firms. Its portfolio breadth provides insulation, though exposure to cyclical markets—particularly life science, semiconductors, and display materials—creates natural headwinds. The core vulnerabilities are demand swings in Life Science, clinical or R&D failures in Healthcare, intensifying competition and industry consolidation in tools and materials, and the inherent capex and technology cycles in Electronics.Thermo Fisher Scientific Inc. (TMO.NYSE)Danaher Corporation (DHR.NYSE)Sartorius AG (SRT3.XETRA)Agilent Technologies, Inc. (A.NYSE)Entegris, Inc. (ENTG.NASDAQ)BASF SE (BAS.XETRA)Novartis AG (NOVN.SIX)Roche Holding AG (ROG.SIX)These competitors influence pricing power, growth opportunities and relative valuation.

Question 9

When does Merck KGaA report earnings?

Accepted Answer

Merck KGaA's next earnings report date is August 6, 2026.

Merck KGaA Earnings

Earnings history & estimates

Historical earnings performance

Upcoming earnings report

Analyst estimates for upcoming periods

Get More Stock Analyses Like This

Unlock Premium

Full Analysis

Ready for professional stock analysis?

Try for Free

Learn more